New Drug Breakthrough: Arixstra Reduces Risk of Fatal Blood Clots in Airline Passengers and Orthopaedic Patients

The video discusses the dangers of developing fatal blood clots, particularly during flights and after major surgeries like hip replacements. It explains how blood clots can lead to pulmonary embolism, a potentially fatal condition. The risk of deep vein thrombosis (DVT) is highlighted, especially with the expected increase in hip surgeries. A new drug, Arixstra, shows promising results in reducing DVT risk by 96% when used post-surgery. With hip fractures projected to rise globally, Arixstra could play a crucial role in preventing DVT in orthopedic patients.

What percentage of orthopaedic patients can develop DVT?

How does the new drug Arixstra help in preventing DVT?